Johnson & Johnson (NYSE:JNJ) Reaches New 52-Week High – Should You Buy?

Shares of Johnson & Johnson (NYSE:JNJ) reached a new 52-week high on Wednesday . The company traded as high as $215.73 and last traded at $217.0040, with a volume of 964463 shares traded. The stock had previously closed at $213.65.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Delaware Supreme Court trimmed part of a $1B damages award tied to the Auris Health (robotics) deal and ordered recalculation, lowering J&J’s potential liability and legal uncertainty. Delaware court reduces $1B loss
• Positive Sentiment: J&J reported strong long-term results for Rybrevant in RAS/BRAF wild-type metastatic colorectal cancer at ASCO — positive efficacy data that can support oncology sales/label expansion. Rybrevant study results
• Positive Sentiment: MedTech momentum: analysts point to cardiovascular strength and recent product rollouts as drivers ahead of J&J’s Q4 release, supporting expectations for continued unit growth. MedTech growth preview
• Positive Sentiment: New CNS data: J&J is presenting Phase 3 analyses for CAPLYTA and other depression-related programs at ACNP, adding potential upside to the psychiatry franchise. Depression data at ACNP
• Neutral Sentiment: J&J is scheduled to report quarterly earnings (projection alerts) this week — a standard near-term event that could move the stock depending on guidance and results. Earnings projection notice
• Neutral Sentiment: Management’s JPM Healthcare Conference presentation transcript is available; investors will parse commentary on strategy, buybacks/dividends and unit outlooks. JPM conference transcript
• Neutral Sentiment: Coverage pieces and investor letters (Q4 reviews, “Dogs of the Dow” mentions) highlight J&J’s dividend yield and stability—supportive for income investors but not immediate catalysts. Dividend / Dogs of the Dow article

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on JNJ. Barclays lifted their target price on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 30th. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $193.00 to $208.00 and gave the company a “market perform” rating in a report on Friday. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Argus set a $210.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Finally, Guggenheim boosted their price objective on shares of Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a report on Friday, December 5th. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Stock Performance

The firm’s 50-day moving average price is $203.88 and its two-hundred day moving average price is $185.81. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a market cap of $522.67 billion, a price-to-earnings ratio of 20.97, a PEG ratio of 2.15 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 14th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.76 by $0.04. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $23.99 billion during the quarter, compared to analysts’ expectations of $23.73 billion. During the same period last year, the business posted $2.42 EPS. Johnson & Johnson’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s payout ratio is currently 50.19%.

Hedge Funds Weigh In On Johnson & Johnson

Large investors have recently made changes to their positions in the stock. SOA Wealth Advisors LLC. boosted its stake in Johnson & Johnson by 0.7% during the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after buying an additional 53 shares in the last quarter. Ethos Financial Group LLC lifted its holdings in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock valued at $1,689,000 after buying an additional 53 shares during the last quarter. Pinnacle Holdings LLC raised its holdings in shares of Johnson & Johnson by 0.5% during the 3rd quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock valued at $2,079,000 after purchasing an additional 54 shares in the last quarter. Bouchey Financial Group Ltd lifted its position in shares of Johnson & Johnson by 0.8% in the third quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company’s stock worth $1,344,000 after buying an additional 54 shares during the last quarter. Finally, Boltwood Capital Management boosted its position in Johnson & Johnson by 1.3% during the fourth quarter. Boltwood Capital Management now owns 4,263 shares of the company’s stock worth $882,000 after purchasing an additional 54 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.